Outset Medical reports Q3 EPS ($1.00), consensus (65c)

Reports Q3 revenue $29.4M, consensus $30.7M. Total cash, including restricted cash, cash equivalents and short-term investments, was $182M as of September 30. “Hospital demand continues to grow as a result of the clinical, operational and financial benefits that can be achieved by insourcing dialysis with Outset’s proven technology, expert know-how and exceptional service,” said Leslie Trigg, CEO. “We entered the second half of the year with work remaining in our commercial transformation, and while we have made good progress, the expected timing to close several large opportunities forecasted for the second half of 2025 has shifted. These opportunities remain in the final stages of our sales process and are now expected to close over the fourth quarter and into early 2026.”